Outlook Therapeutics (OTLK) Treasury Shares (2015 - 2024)
Outlook Therapeutics (OTLK) posted quarterly Treasury Shares of $123.0 for Q1 2024, down 95.02% year-over-year from $2470.0 in Q2 2023, and down 95.02% quarter-over-quarter from $2470.0 in Q4 2023.
Outlook Therapeutics (OTLK) Treasury Shares (2015 - 2024) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Treasury Shares for 10 consecutive years, with $123.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Treasury Shares fell 95.02% year-over-year to $123.0; the TTM figure through Mar 2024 stood at $123.0 (down 95.02% YoY), while the FY2023 annual figure was $123.0, down 95.02% from the prior year.
- Treasury Shares eased to $123.0 in Q1 2024 per OTLK's latest filing, from $2470.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $2470.0 in Q2 2020 and bottomed at $123.0 in Q3 2023.
- Historically, Treasury Shares has averaged $2176.6 across 5 years, with a median of $2470.0 in 2020.
- Annual changes were most pronounced in 2020 — Treasury Shares changed 0.0% — and 2023, when it plunged 95.02%.
- Outlook Therapeutics' Treasury Shares stood at $2470.0 in 2020, then changed by 0.0% to $2470.0 in 2021, then changed by 0.0% to $2470.0 in 2022, then changed by 0.0% to $2470.0 in 2023, then slumped by 95.02% to $123.0 in 2024.
- Business Quant data shows OTLK's Treasury Shares at $123.0 in Q1 2024, $2470.0 in Q4 2023, and $123.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 123.00 |
| Mar 31, 2024 | 123.00 |
| Dec 31, 2023 | 2,470.00 |
| Dec 31, 2023 | 2,470.00 |
| Sep 30, 2023 | 123.00 |
| Sep 30, 2023 | 123.00 |
| Jun 30, 2023 | 2,470.00 |
| Jun 30, 2023 | 2,470.00 |
| Mar 31, 2023 | 2,470.00 |
| Mar 31, 2023 | 2,470.00 |
| Dec 31, 2022 | 2,470.00 |
| Dec 31, 2022 | 2,470.00 |
| Sep 30, 2022 | 2,470.00 |
| Sep 30, 2022 | 2,470.00 |
| Jun 30, 2022 | 2,470.00 |
| Jun 30, 2022 | 2,470.00 |
| Mar 31, 2022 | 2,470.00 |
| Mar 31, 2022 | 2,470.00 |
| Dec 31, 2021 | 2,470.00 |
| Dec 31, 2021 | 2,470.00 |